其它产品项目整合

项目整合的本质是一项集合成方法学、反应工程学与过程分析技术于一体的系统工程。其核心逻辑可以概括为以下几点：源头优选：利用如N-硝胺化学等底层方法学突破，从分子层面颠覆传统高成本、高污染路线。过程强化：依托连续流技术，攻克有机金属试剂应用、光化学反应放大等“不可能”任务，实现高危工艺的本质安全。系统集成：整合“反应-淬灭-分离”全流程，利用微流控与在线分析技术，消除批次间的差异，实现药品制造的连续化与智能化。当前，中间体工艺研发正在经历从“经验驱动”向“数据驱动”的转变。AI辅助路线设计、自动化高通量筛选与连续制造平台的结合，将使得“分子结构与最优工艺路径”之间的映射关系逐渐清晰。未来的竞争优势，将属于那些能够将底层化学创新与先进工程技术进行无缝整合的研发体系。
备注: 根据相关法律法规, 本站点不显示有法律约束管制的产品, 如有遗漏, 请自行鉴别,或提交我们及时更新撤除.
如有产品相关项目调研推广服务, 请致函联系我们

客户展示

其它产品项目整合

Valrubicin CAS Registry Number: 56124-62-0 戊柔比星

CAS Name: Pentanoic acid 2-[(2S,4S)-1,2,3,4,6,11-hexahydro-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-4-[[2,3,6-trideoxy-3-[(trifluoroacetyl)amino]-a-L-lyxo-hexopyranosyl]oxy]-2-naphthacenyl]-2-oxoeth...
Literature References: Semisynthetic doxorubicin, q.v., analog. Prepn: M. Israel et al., Cancer Res. 35, 1365 (1975); M. Israel, E. J. Modest, US 4035566 (1977 to S. Farber Cancer Inst.). TLC determn in biological samples: B. Barbieri et al., J. Chromatogr. 163, 195 (1979). Clinical pharmacokinetics: R. E. Greenberg et al., Urology 49, 471 (1997). Clinical trial in refractory bladder cancer: G. Steinberg et al., J. Urol. 163, 761 (2000). Review of pharmacology and clinical development: C. Doehn, Curr. Opin. Oncol. Endocr. Metab. Invest. Drugs 1, 407-415 (1999); S. V. Onrust, H. M. Lamb, Drugs Aging 15, 69-75 (1999).

Caspofungin CAS Registry Number: 162808-62-0 卡泊芬净

CAS Name: 1-[(4R,5S)-5-[(2-Aminoethyl)amino]-N2-(10,12-dimethyl-1-oxotetradecyl)-4-hydroxy-L-ornithine]-5-[(3R)-3-hydroxy-L-ornithine]-pneumocandin B0
Percent Composition: C 57.13%, H 8.11%, N ...
Literature References: Semisynthetic echinocandin antifungal that inhibits 1,3-b-D-glucan synthase which is required for cell wall synthesis. Prepn: J. M. Balkovec et al., WO 9421677; eidem, US 5378804 (1994, 1995 both to Merck Co.). HPLC/MS determn in plasma: C. M. Chavez-Eng et al., J. Chromatogr. B 721, 229 (1999). Clinical study vs amphotericin B, q.v. in Candida esophagitis: A. Villanueva et al., Clin. Infect. Dis. 33, 1529 (2001). Review of in vitro antifungal activity, pharmacology and clinical development: A. H. Groll, T. J. Walsh, Expert Opin. Invest. Drugs 10, 1545-1558 (2001); A. Hoang, Am. J. Health-Syst. Pharm. 58, 1206-1214 (2001).

Micafungin CAS Registry Number: 235114-32-6 米卡芬净

CAS Name: 1-[(4R,5R)-4,5-Dihydroxy-N2-[4-[5-[4-(pentyloxy)phenyl]-3-isoxazolyl]benzoyl]-L-ornithine]-4-[(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonine]pneumocandin A0
Percent Compo...
Literature References: Semisynthetic echinocandin antifungal; inhibits 1,3-b-glucan synthase. Prepn (stereochem unspec): H. Ohki et al., WO 9611210; eidem, US 6107458 (1996, 2000 both to Fujisawa). Synthesis and antifungal activity: M. Tomishima et al., J. Antibiot. 52, 674 (1999). Antifungal spectrum in vitro: S. Tawara et al., Antimicrob. Agents Chemother. 44, 57 (2000). Pharmacokinetics and antifungal efficacy: V. Petraitis et al., ibid. 46, 1857 (2002). Review of pharmacology and therapeutic potential: A. H. Groll, T. J. Walsh, Curr. Opin. Anti-Infect. Invest. Drugs 2, 405-412 (2000); A. H. Groll et al., Expert Opin. Invest. Drugs 14, 489-509 (2005).

Methylergonovine CAS Registry Number: 113-42-8 甲麦角新碱

CAS Name: (8b)-9,10-Didehydro-N-[(1S)-1-(hydroxymethyl)propyl]-6-methylergoline-8-carboxamide
Additional Names: N-[a-(hydroxymethyl)propyl]-D-lysergamide; D-lysergic acid (+)-butanolamide-(2); ...
Literature References: Semisynthetic ergot alkaloid; metabolite of methysergide, q.v. Prepn: A. Stoll, A. Hofmann, US 2265207 (1941 to Sandoz); eidem, Helv. Chim. Acta 26, 944 (1943). HPLC determn in plasma: H. T. Smith, N. C. Molinaro, J. Chromatogr. 424, 416 (1988). Clinical trial in prevention of cluster headache: L. Mueller et al., Headache 37, 437 (1997). Review of pharmacology and clinical use in obstetrics and gynecology: A. N. de Groot et al., Drugs 56, 523-535 (1998).

Roxithromycin CAS Registry Number: 80214-83-1 罗红霉素

CAS Name: Erythromycin 9-[O-[(2-methoxyethoxy)methyl]oxime]
Additional Names: oxacyclotetradecane erythromycin deriv; 9-(2',5'-dioxahexyloxyimino)erythromycinTrademarks: Assoral (Glaxo); Claram...
Literature References: Semisynthetic erythromycin derivative. Prepn: S. Gouin d¢Ambrieres et al., FR 2473525; eidem, US 4349545 (1981, 1982 both to Roussel-UCLAF). In vitro antibacterial spectrum: R. N. Jones et al., Antimicrob. Agents Chemother. 24, 209 (1983); Y. J. Drabu et al., Drugs Exp. Clin. Res. 13, 201 (1987). Antiprotozoal activity in mice: B. J. Luft, Eur. J. Clin. Microbiol. 6, 479 (1987); H. R. Chang, J.-C. R. Pechere, Antimicrob. Agents Chemother. 31, 1147 (1987). Pharmacokinetics: R. Wise et al., ibid. 1051. Bioassay in biological fluids: A. L. Barry, R. R. Packer, Eur. J. Clin. Microbiol. 5, 536 (1986). Clinical evaluations in respiratory tract infections: J. M. Lachat et al., Schweiz. Med. Wochenschr. 116, 1739 (1986); C. Grassi et al., Chemioterapia 6, 41 (1987). Series of articles on antimicrobial activity, pharmacokinetics and clinical efficacy: J. Antimicrob. Chemother. 20, Suppl. B, 1-185 (1987).

Oritavancin CAS Registry Number: 171099-57-3 奥利万星

CAS Name: (4''R)-22-O-(3-Amino-2,3,6-trideoxy-3-C-methyl-a-L-arabino-hexopyranosyl)-N3''-[(4'-chloro[l,1'-biphenyl]-4-yl)methyl]vancomycinPercent Composition: C 57.61%, H 5.45%, Cl 5.93%, N 7.81%,...
Literature References: Semisynthetic glycopeptide antibiotic. Prepn: R. D. G. Cooper et al., WO 9630401; eidem US 5840684 (1996, 1998 both to Eli Lilly). In vitro antibacterial activity: F. Biavasco et al., Antimicrob. Agents Chemother. 41, 2165 (1997). Mechanism of action: N. E. Allen, T. I. Nicas, FEMS Microbiol. Rev. 26, 511 (2003). Clinical pharmacokinetics: S. M. Bhavnani et al., Diagn. Microbiol. Infect. Dis. 50, 95 (2004); G. J. Fetterly et al., Antimicrob. Agents Chemother. 49, 148 (2005). Clinical evaluation in Staphylococcus aureus bacteremia: S. M. Bhavnani et al., ibid. 50, 994 (2006). Review of pharmacology and clinical development: D. R. P. Guay, Pharmacotherapy 24, 58-68 (2004).

Temocillin CAS Registry Number: 66148-78-5 替莫西林

CAS Name: (2S,5R,6S)-6-[(Carboxy-3-thienylacetyl)amino]-6-methoxy-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid
Additional Names: (6S)-6-[2-carboxy-2-(3-thienyl)acetami...
Literature References: Semi-synthetic injectable penicillin deriv with high activity vs a large number of gram-negative bacteria, but with little activity vs gram-positive organisms. Prepn: J. P. Clayton, P. H. Bentley, DE 2600866 (1976 to Beecham), C.A. 86, 55420t (1977); P. H. Bentley et al., J. Chem. Soc. Perkin Trans. 1 1979, 2455. In vitro antibacterial activity and b-lactamase susceptibility: I. Phillips et al., J. Antimicrob. Chemother. 10, 271 (1982). Comparison to other penicillins vs H. influenzae and intestinal gram-negative rods: H. Y. Chen, J. D. Williams, ibid. 279. Pharmacokinetics and tissue penetration in healthy volunteers: R. M. Brown et al., ibid. 295. In vivo and in vitro comparison to ampicillin: R. Yogev et al., Antimicrob. Agents Chemother. 23, 182 (1983). Series of articles on microbiology, pharmacology and clinical studies: Drugs 29, Suppl. 5, 1-243 (1985).

Pirlimycin CAS Registry Number: 79548-73-5 吡利霉素

CAS Name: (2S-cis)-Methyl 7-chloro-6,7,8-trideoxy-6-[[(4-ethyl-2-piperidinyl)carbonyl]amino]-1-thio-L-threo-a-D-galactooctopyranoside
Percent Composition: C 49.68%, H 7.60%, Cl 8.63%, N 6.82%, ...
Literature References: Semi-synthetic lincosaminide antibiotic; structural analog of clindamycin, q.v. Prepn: R. D. Birkenmeyer, DE 3043502; idem, US 4278789 (both 1981 to Upjohn); R. D. Birkenmeyer et al., J. Med. Chem. 27, 216 (1984). In vitro activity vs aerobic bacteria: V. I. Ahonkhai et al., Antimicrob. Agents Chemother. 21, 902 (1982); vs anaerobic bacteria: S. M. H. Qadri et al., J. Antibiot. 36, 42 (1983). HPLC determn in biological fluids: J. A. Shah, D. J. Weber, J. Chromatogr. 309, 95 (1984). Ion-pairing LC determn in pharmaceutic prepns: D. L. Theis, ibid. 402, 335 (1987). Metabolism and residue studies in dairy cows: R. E. Hornish et al., ACS Symp. Ser. 503, 132-147 (1992). Evaluation in bovine mastitis: W. E. Owens et al., Agri-Pract. 15, 19 (1994).

Telithromycin CAS Registry Number: 191114-48-4 泰利霉素

CAS Name: 3-De[(2,6-dideoxy-3-C-methyl-3-O-methyl-a-L-ribohexopyranosyl)oxy]-11,12-dideoxy-6-O-methyl-3-oxo-12,11-[oxycarbonyl[[4-[4-(3-pyridinyl)-1H-imidazol-1-yl]butyl]imino]]erythromycinTradema...
Literature References: Semisynthetic macrolide antibiotic of the ketolide class, a group of erythromycin derivatives in which the L-cladinose residue has been replaced by a 3-keto group. Prepn: C. Agouridas et al., EP 680967; eidem, US 5635485 (1995, 1997 both to Roussel Uclaf); A. Denis et al., Bioorg. Med. Chem. Lett. 9, 3075 (1999). In vitro activity vs anaerobic bacteria: L. M. Ednie et al., Antimicrob. Agents Chemother. 41, 2019 (1997); vs gram-positive bacteria: K. Malathum et al., ibid. 43, 930 (1999). Time-kill kinetics: F. J. Boswell et al., J. Antimicrob. Chemother. 41, 149 (1998). HPLC analysis: B. Lingerfelt, W. S. Champney, J. Pharm. Biomed. Anal. 20, 459 (1999). Review of pharmacology and clinical trials: G. Ackermann, A. C. Rodloff, J. Antimicrob. Chemother. 51, 497-511 (2003).

Cethromycin CAS Registry Number: 205110-48-1 喹红霉素

CAS Name: (3aS,4R,7R,9R,10R,11R,13R,15R,15aR)-4-Ethyloctahydro-3a,7,9,11,13,15-hexamethyl-11-[[3-(3-quinolinyl)-2-propenyl]oxy]-10-[[3,4,6-trideoxy-3-(dimethylamino)-b-D-xylohexopyranosyl]oxy]-2H-...
Literature References: Semisynthetic macrolide antibiotic of the ketolide class; structurally similar to telithromycin, q.v. Prepn: Y. S. Or et al., WO 9809978; eidem, US 5866549 (1998, 1999 both to Abbott); eidem, J. Med. Chem. 43, 1045 (2000). Improved prepn: D. J. Plata et al., Tetrahedron 60, 10171 (2004). Comparative in vitro antibacterial spectrum: A. M. Nilius et al., Antimicrob. Agents Chemother. 45, 2163 (2001). Mechanism of action study: W. S. Champney, J. Pelt, Curr. Microbiol. 45, 155 (2002). HPLC-MS determn in biological samples: Q. Ren et al., J. Chromatogr. Sci. 41, 494 (2003). Clinical pharmacokinetics: M. W. Pletz et al., Antimicrob. Agents Chemother. 47, 1129 (2003). Reviews of development and therapeutic potential: L. E. Lawrence, Curr. Opin. Invest. Drugs 2, 766-772 (2001); T. J. Dougherty, J. F. Barrett, Expert Opin. Invest. Drugs 10, 343-351 (2001).